Nifty
:
24636.00
Sensex
:
78954.76
11.35 (0.05%)
373.76 (0.48%)
Nifty
Sensex
:
:
24636.00
78954.76
11.35 (0.05%)
373.76 (0.48%)

Mankind Pharma Ltd.

Pharmaceuticals & Drugs

Rating :
63/99

BSE: 543904 | NSE: MANKIND

NSE BSE
2420.30
06-Aug-2026
  • Open
  • High
  • Low
  • Previous Close
  •  2450
  •  2463.8
  •  2420.3
  •  2435.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  241909
  •  590294167.7
  •  2674
  •  1909.7

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,00,395.19
  • 49.15
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,05,934.20
  • N/A
  • 5.97

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 72.63%
  • 1.04%
  • 1.29%
  • FII
  • DII
  • Others
  • 9.45%
  • 12.41%
  • 3.18%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.54
  • 12.91
  • 11.64

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.59
  • 12.72
  • 7.57

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.00
  • 5.94
  • 0.02

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 51.78

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 7.74

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 31.24

Earnings Forecasts:

(Updated: 01-08-2026)
Description
2026
2027
2028
2029
Adj EPS
53
7
25.65
44.98
P/E Ratio
45.67
345.76
94.36
53.81
Revenue
43.16
35.02
29.59
14275.4
EBITDA
15984
17793.1
19243.9
3508.09
Net Income
4148.11
4731.98
5073.1
1885.05
ROA
2386.87
2936.02
3472.59
6.84
P/B Ratio
1.17
-3.17
-0.51
6.15
ROE
5.48
4.77
4.16
12.24
FCFF
13.57
14.65
15.49
2101.44
FCFF Yield
2475.79
3029.58
3413.68
1.96
Net Debt
2.31
2.82
3.18
4151.5
BVPS
2062.98
-763.75
-4700
393.38

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
4,030.59
3,570.35
12.89%
3,442.93
3,079.37
11.81%
3,567.20
3,198.79
11.52%
3,697.16
3,061.43
20.77%
Expenses
2,974.40
2,723.58
9.21%
2,513.05
2,396.18
4.88%
2,647.77
2,382.80
11.12%
2,775.83
2,214.24
25.36%
EBITDA
1,056.19
846.77
24.73%
929.88
683.19
36.11%
919.43
815.99
12.68%
921.33
847.19
8.75%
EBIDTM
26.20%
23.72%
27.01%
22.19%
25.77%
25.51%
24.92%
27.67%
Other Income
45.00
79.88
-43.67%
114.29
251.33
-54.53%
72.75
77.00
-5.52%
91.87
109.06
-15.76%
Interest
109.98
170.65
-35.55%
141.75
190.54
-25.61%
157.20
220.93
-28.85%
169.68
7.10
2,289.86%
Depreciation
225.70
218.68
3.21%
223.08
230.87
-3.37%
222.60
187.17
18.93%
221.82
100.49
120.74%
PBT
765.51
537.32
42.47%
656.18
513.11
27.88%
505.79
484.89
4.31%
621.70
848.66
-26.74%
Tax
195.36
95.87
103.78%
99.75
86.44
15.40%
95.12
110.46
-13.89%
103.84
189.98
-45.34%
PAT
570.15
441.45
29.15%
556.43
426.67
30.41%
410.67
374.43
9.68%
517.86
658.68
-21.38%
PATM
14.15%
12.36%
16.16%
13.86%
11.51%
11.71%
14.01%
21.52%
EPS
13.75
10.62
29.47%
13.43
10.20
31.67%
9.90
9.22
7.38%
12.39
16.31
-24.03%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
14,737.88
14,277.64
12,207.44
10,260.44
8,749.43
7,781.56
6,214.43
5,871.87
4,979.98
4,920.74
4,382.26
Net Sales Growth
14.16%
16.96%
18.98%
17.27%
12.44%
25.22%
5.83%
17.91%
1.20%
12.29%
 
Cost Of Goods Sold
4,096.80
4,052.12
3,489.04
3,198.47
2,913.64
2,421.73
1,780.60
1,878.07
1,721.34
1,670.59
1,585.80
Gross Profit
10,641.08
10,225.52
8,718.40
7,061.97
5,835.79
5,359.83
4,433.82
3,993.80
3,258.64
3,250.16
2,796.46
GP Margin
72.20%
71.62%
71.42%
68.83%
66.70%
68.88%
71.35%
68.02%
65.43%
66.05%
63.81%
Total Expenditure
10,911.05
10,655.26
9,186.97
7,745.27
6,847.50
5,791.01
4,565.32
4,427.16
4,054.95
3,927.09
3,531.31
Power & Fuel Cost
-
183.71
149.49
125.16
108.96
103.13
82.53
79.96
64.15
41.71
24.57
% Of Sales
-
1.29%
1.22%
1.22%
1.25%
1.33%
1.33%
1.36%
1.29%
0.85%
0.56%
Employee Cost
-
3,183.90
2,692.37
2,260.60
1,918.47
1,620.59
1,415.78
1,335.53
1,094.79
1,076.75
883.58
% Of Sales
-
22.30%
22.06%
22.03%
21.93%
20.83%
22.78%
22.74%
21.98%
21.88%
20.16%
Manufacturing Exp.
-
337.05
216.03
172.71
150.57
160.29
140.14
109.22
85.46
104.83
72.85
% Of Sales
-
2.36%
1.77%
1.68%
1.72%
2.06%
2.26%
1.86%
1.72%
2.13%
1.66%
General & Admin Exp.
-
1,424.20
1,314.02
939.49
1,000.80
655.99
451.75
439.00
508.16
424.35
362.38
% Of Sales
-
9.98%
10.76%
9.16%
11.44%
8.43%
7.27%
7.48%
10.20%
8.62%
8.27%
Selling & Distn. Exp.
-
1,325.12
1,164.71
924.26
638.11
708.17
587.73
426.72
521.81
541.84
557.66
% Of Sales
-
9.28%
9.54%
9.01%
7.29%
9.10%
9.46%
7.27%
10.48%
11.01%
12.73%
Miscellaneous Exp.
-
149.16
161.31
124.58
116.96
121.10
106.78
158.66
59.24
67.04
557.66
% Of Sales
-
1.04%
1.32%
1.21%
1.34%
1.56%
1.72%
2.70%
1.19%
1.36%
1.01%
EBITDA
3,826.83
3,622.38
3,020.47
2,515.17
1,901.93
1,990.55
1,649.11
1,444.71
925.03
993.65
850.95
EBITDA Margin
25.97%
25.37%
24.74%
24.51%
21.74%
25.58%
26.54%
24.60%
18.57%
20.19%
19.42%
Other Income
323.91
358.79
536.79
280.22
128.57
196.03
170.95
103.78
52.92
72.06
89.08
Interest
578.61
644.25
431.95
34.24
45.76
59.80
21.16
23.24
44.24
25.22
3.64
Depreciation
893.20
886.18
621.22
378.42
325.92
166.62
118.97
99.06
69.03
45.83
30.79
PBT
2,549.18
2,450.74
2,504.09
2,382.73
1,658.81
1,960.15
1,679.93
1,426.20
864.66
994.67
905.60
Tax
494.07
394.58
509.74
457.15
361.56
521.64
398.58
381.59
264.12
322.87
289.69
Tax Rate
19.38%
17.00%
20.36%
19.19%
21.80%
26.61%
23.73%
26.76%
30.55%
32.46%
31.99%
PAT
2,055.11
1,912.93
1,986.43
1,911.92
1,281.86
1,433.48
1,265.42
1,030.42
578.53
643.72
615.91
PAT before Minority Interest
2,030.21
1,938.10
2,006.59
1,940.79
1,309.68
1,452.96
1,293.03
1,056.14
610.48
671.80
615.91
Minority Interest
-24.90
-25.17
-20.16
-28.87
-27.82
-19.48
-27.61
-25.72
-31.95
-28.08
0.00
PAT Margin
13.94%
13.40%
16.27%
18.63%
14.65%
18.42%
20.36%
17.55%
11.62%
13.08%
14.05%
PAT Growth
8.09%
-3.70%
3.90%
49.15%
-10.58%
13.28%
22.81%
78.11%
-10.13%
4.52%
 
EPS
49.76
46.32
48.10
46.29
31.04
34.71
30.64
24.95
14.01
15.59
14.91

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
16,300.34
14,332.39
9,363.09
7,435.22
6,155.23
4,722.00
3,485.31
2,823.05
2,880.91
2,927.14
Share Capital
41.28
41.26
40.06
40.06
40.06
40.06
40.06
40.06
40.06
20.03
Total Reserves
16,211.34
14,247.46
9,299.78
7,395.10
6,115.17
4,681.94
3,445.25
2,782.99
2,840.85
2,907.11
Non-Current Liabilities
4,686.53
7,419.90
187.34
199.24
168.68
107.33
103.04
77.79
49.19
53.24
Secured Loans
2,482.65
5,077.83
24.87
23.15
48.94
57.42
58.19
25.11
2.70
1.43
Unsecured Loans
338.58
448.36
0.00
0.00
0.25
0.25
0.00
0.00
0.34
1.25
Long Term Provisions
248.65
155.06
123.12
97.89
80.00
72.24
63.00
44.92
35.63
25.04
Current Liabilities
6,507.25
5,663.56
2,119.73
1,863.14
2,623.46
1,353.40
1,250.73
1,024.06
1,296.24
662.57
Trade Payables
1,341.33
1,133.40
777.06
1,008.18
1,076.40
666.97
745.11
561.97
649.14
491.82
Other Current Liabilities
3,702.35
1,335.07
755.50
386.05
472.89
282.77
180.05
116.53
161.51
140.02
Short Term Borrowings
638.92
2,513.14
151.48
115.02
794.59
158.35
44.28
241.46
404.15
9.94
Short Term Provisions
824.65
681.95
435.69
353.89
279.59
245.30
281.29
104.10
81.44
20.80
Total Liabilities
27,754.83
27,651.64
11,882.86
9,685.67
9,108.45
6,323.62
5,025.34
4,083.52
4,360.47
3,741.01
Net Block
18,620.45
19,004.48
4,539.95
4,245.28
3,582.77
1,658.94
1,594.04
1,399.46
1,013.77
793.31
Gross Block
21,376.79
20,916.96
5,909.74
5,233.03
4,246.54
2,160.04
1,987.79
1,681.37
1,229.77
915.35
Accumulated Depreciation
2,756.34
1,912.48
1,369.79
987.75
663.78
501.10
372.99
281.91
216.00
122.04
Non Current Assets
20,800.63
20,663.37
5,314.64
5,357.80
4,701.63
2,416.98
2,203.13
2,085.41
1,786.75
1,672.00
Capital Work in Progress
1,127.63
825.67
281.80
550.15
701.47
371.95
316.95
327.87
525.07
301.66
Non Current Investment
447.87
351.09
309.81
270.95
235.01
205.80
164.39
215.66
139.38
100.98
Long Term Loans & Adv.
554.72
293.08
163.97
187.54
163.88
158.07
106.06
117.69
77.10
259.59
Other Non Current Assets
49.91
189.00
13.79
98.51
13.09
16.72
16.12
14.35
8.52
9.07
Current Assets
6,951.50
6,985.57
6,565.52
4,324.56
4,403.84
3,879.62
2,819.50
1,943.15
2,573.71
2,069.01
Current Investments
1,537.31
1,690.84
2,258.11
1,075.47
874.46
1,306.17
665.03
543.27
649.87
847.94
Inventories
2,144.48
2,093.71
1,553.46
1,498.46
1,760.24
1,183.54
899.13
820.99
789.25
788.87
Sundry Debtors
1,729.51
1,538.34
848.28
576.42
388.17
330.61
531.09
220.22
296.67
166.46
Cash & Bank
482.77
554.50
708.10
453.20
405.94
700.74
419.88
141.01
138.95
145.87
Other Current Assets
1,057.43
97.42
104.10
64.29
975.03
358.56
304.37
217.67
698.97
119.88
Short Term Loans & Adv.
956.70
1,010.76
1,093.47
656.71
804.29
275.79
294.21
209.18
230.00
88.91
Net Current Assets
444.25
1,322.01
4,445.79
2,461.42
1,780.37
2,526.22
1,568.77
919.09
1,277.48
1,406.44
Total Assets
27,752.13
27,648.94
11,880.16
9,682.36
9,105.47
6,296.60
5,022.63
4,028.56
4,360.46
3,741.01

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Cash From Operating Activity
3,121.29
2,413.38
2,152.44
1,813.30
919.78
1,137.24
PBT
2,332.68
2,524.78
2,399.35
1,671.24
1,974.60
1,691.61
Adjustment
1,276.52
601.79
212.19
298.43
30.81
-5.66
Changes in Working Capital
104.82
-146.44
-17.57
166.73
-586.12
-94.63
Cash after chg. in Working capital
3,714.02
2,980.13
2,593.97
2,136.40
1,419.29
1,591.32
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-592.73
-566.75
-441.53
-323.10
-499.51
-454.07
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-196.42
-12,682.95
-2,081.69
-1,054.13
-1,369.14
-1,222.21
Net Fixed Assets
-445.48
-1,083.72
-517.31
-591.49
-2,286.21
Net Investments
160.23
-12,468.02
-1,113.13
-576.36
-128.98
Others
88.83
868.79
-451.25
113.72
1,046.05
Cash from Financing Activity
-2,952.69
10,232.56
5.27
-739.73
604.62
-7.81
Net Cash Inflow / Outflow
-27.82
-37.01
76.02
19.44
155.26
-92.78
Opening Cash & Equivalents
403.88
382.01
304.82
283.06
127.33
219.73
Closing Cash & Equivalent
391.69
403.88
382.01
304.82
283.06
127.33

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Book Value (Rs.)
393.72
346.31
233.15
185.61
153.65
117.88
ROA
7.00%
10.15%
18.00%
13.94%
18.83%
22.79%
ROE
12.69%
16.98%
23.14%
19.27%
26.72%
31.51%
ROCE
13.24%
18.32%
28.35%
23.49%
33.96%
39.97%
Fixed Asset Turnover
0.71
0.95
1.92
1.92
2.52
3.00
Receivable days
39.93
34.35
24.35
19.33
16.25
25.31
Inventory Days
51.78
52.50
52.16
65.31
66.57
61.16
Payable days
111.46
99.93
101.86
130.57
131.38
144.73
Cash Conversion Cycle
-19.75
-13.08
-25.35
-45.92
-48.56
-58.26
Total Debt/Equity
0.37
0.58
0.02
0.02
0.14
0.05
Interest Cover
4.62
6.83
71.03
37.52
34.02
80.96

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • Mankind Pharma reports 30% rise in Q1 consolidated net profit
    31st Jul 2026, 11:40 AM

    Consolidated total income of the company increased by 11.65% to Rs 4,075.59 crore in Q1FY27.

    Read More
  • Mankind Pharma - Quarterly Results
    31st Jul 2026, 00:00 AM

    Read More
  • Mankind Pharma gets nod to incorporate wholly owned subsidiary
    11th Jul 2026, 17:03 PM

    The Board of Directors of the company at its meeting held on July 11, 2026, has inter-alia, considered and approved the same

    Read More
  • Mankind Pharma’s arm acquires remaining 10% stake in Upakarma
    3rd Jun 2026, 10:30 AM

    This acquisition will enable the company to achieve better operational efficiencies through streamlined processes

    Read More
  • Mankind Pharma gets nod to invest up to Rs 500 crore in Mankind Medicare
    20th May 2026, 09:30 AM

    The Board of Directors of the Company at its meeting held May 19, 2026, has approved the same

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.